



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/583,923	05/14/2007	Manpreet S. Wadhwa	PC027698A	4848
28523	7590	08/05/2010	EXAMINER	
PFIZER INC. PATENT DEPARTMENT Bld 114 M/S 9114 EASTERN POINT ROAD GROTON, CT 06340				HAMUD, FOZIA M
ART UNIT		PAPER NUMBER		
1647				
			NOTIFICATION DATE	DELIVERY MODE
			08/05/2010	ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

-IPGSGro@pfizer.com

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/583,923	WADHWA ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	FOZIA M. HAMUD	1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 21 May 2010.  
 2a) This action is **FINAL**.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-15 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1-15 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on 20 June 2006 is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | Paper No(s)/Mail Date. _____ .                                    |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>05/21/2010</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application |
|   | 6) <input type="checkbox"/> Other: _____ .                        |

**DETAILED ACTION**

**RCE:**

1a. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 21 May 2010 has been entered.

**Status of Claims:**

1b. Claims 1, 7 and 8 are amended. Claims 1-15 are pending and under consideration.

**Information Disclosure Statement:**

2. The information disclosure statement filed on 21 May 2010 has been received and complies with the provisions of 37 CFR §1.97 and §1.98. The references have been considered as to the merits.

**Response to Applicants' arguments:**

3. The following objection and rejections are withdrawn in light of Applicants' arguments:

I. The rejection of claims 1-15 made under 35 U.S.C. 103(a) as being unpatentable over O'Connor et al (U.S. Patent 6,448,225, issued on 10 September 2002) in view of Patel, Suman, (US patent 5,358,708, issued on 25 October 1994), is withdrawn.

Applicants argue that the '708 patent teaches formulations of an interferon, granulocyte-macrophage colony stimulating factor or an interleukin in a buffer with methionine or histidine, however, it does not teach a formulation comprising hGH or a formulation comprising polyethylene glycol. Applicants' submit that the '225 patent, teaches the use of non-ionic surfactants that include a polysorbate, such as polysorbate 20 or 80, etc. and the poloxamers, such as poloxamer 184 or 188, Pluronic, polyols, but does not teach formulations comprising polyethylene glycol.

Applicants' arguments that the combined teachings of the '708 and the '225 patents teach or suggest any formulation using *polyethylene glycol* as a stabilizer or a formulation comprising hGH, methionine and polyethylene glycol as instantly claimed, are found persuasive.

***New Rejections:***

***Claim Rejections - 35 USC § 103:***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each

claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 1-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over O'Connor et al (U.S. Patent 6,448,225, issued on 10 September 2002) in view of Patel, Suman, (US patent 5,358,708, issued on 25 October 1994), further in view of Cleland et al, (Pharmaceutical research, 1996, Vol. 13, No. 10, pages 1464-1475).

The instant claim 1 is drawn to a formulation comprising a therapeutically effective amount of a human growth hormone, (recombinant) in an aqueous solution, a buffer that maintains the pH of the formulation at a pH of 5 to 7, a ***non-ionic surfactant***, a ***polymer stabilizer***, ***methionine***, and one or more optional excipients selected from the group consisting of a divalent cation present in a magnesium salt selected from the group consisting of magnesium hydroxide, magnesium chloride, magnesium sulfate, magnesium citrate, and magnesium edentate; a tonicity agent; and a preservative, wherein the formulation remains stable after at least one freezing and subsequent thawing event. Claims 2-12, recite specific concentrations and/or excipients. Claim 13 recites that the formulation remains in solution after exposure to three or more freeze-thaw events, claims 14-15 further limit the invention regarding time that the formulation remains stable and that total deamidation is measured by anion exchange HPLC.

U.S. Patent 6,448,225, (O'Connor et al) teach a stable aqueous formulation of human growth hormone, (recombinant) comprising human growth hormone, citrate, phosphate, Tris, succinate, or histidine buffer, (2 mM to 50 mM), providing pH 5.5 to pH 7, nonionic surfactant, (polysorbate 20 or 80, 0.1% to 5%), polyethylene polymer,

Art Unit: 1647

tonicity agent, (sorbitol) and preservative, (phenol or benzyl alcohol), (see column 3, lines 1-3 and column 3, line 30 to column 4, line 22). O'Connor et al teach that their formulation is stable upon storage for 6 to 18 months at 2 to 8<sup>0</sup> C and that deamidation was measured by anion exchange chromatography, (see column 5, line 51 to column 6, line 50).

However, '225 reference does not teach formulations of human growth hormone that also comprise methionine or polyethylene glycol.

US patent 5,358,708, (Patel, Suman) teaches aqueous formulations of an interferon, a granulocyte-macrophage colony-stimulating factor or an interleukin having extended storage lifetimes by adding methionine to said formulations, (see column 3, line 59 to column 4, line 33, figures 1 and 2 and claims).

Cleland et al teach stable formulations of human growth hormone that are formulated with polyethylene glycol for stability and improved yield, (see abstract, pages 1467-1468).

Therefore, it would have been obvious to the person of ordinary skill in the art at the time the invention was made, to modify the formulations of human growth hormone taught by '225 patent by adding methionine and polyethylene glycol to said formulation with great expectation of success by following the techniques taught by the '708 and Cleland et al references, which teach the benefit of using methionine to extend the storage lifetimes of formulations of recombinant proteins and the benefit of using polyethylene glycol for improved yield, respectively.

One of ordinary skill would have achieved the predictable result of obtaining a stable liquid formulation of human growth hormone with extended storage lifetime with a great expectation of success by following the techniques taught by the O'Connor et al, Patel and Cleland et al references. One of ordinary skill would have been able to manipulate concentrations of buffers and excipients to obtain optimum stability. The person of ordinary skill in the art would have been motivated to make human growth hormone in a stable liquid formulation with extended storage lifetime, because growth hormone is used clinically to treat children's growth disorders and adult growth hormone deficiency. Therefore, it is of great importance to obtain stable human growth hormone formulations with extended storage lifetime to improve efficacy and prevent undesirable byproducts such as aggregates during processing and storage. Accordingly, the invention, taken as a whole, is *prima facie* obvious over the cited prior art.

***Response to Applicants' Arguments:***

Applicants submit that the combined teachings of '225 and '708 references do not teach or suggest a formulation comprising hGH, methionine and polyethylene glycol. The '708 patent teaches formulations of an interferon, granulocyte-macrophage colony stimulating factor or an interleukin in a buffer with methionine or histidine. Applicants also submit that one of ordinary skill in the art would not be motivated to modify the combination of O'Conner and Patel to arrive at the instantly claimed invention since there is no motivation to do so.

Applicants argue that the obviousness rejection is based on combination of Patel et. al., ('708), which references the use of methionine as a stabilizer without the use of a

Art Unit: 1647

polymer stabilizer for an interleukin, interferon, and granulocyte macrophage colony stimulating factor with the O'Conner, ('225), which teaches hGH formulation, but lacks both the polymer stabilizer and methionine. One of ordinary skill in the art would not be motivated to modify the combination of O'Conner and Patel since the use of methionine as a stabilizer is not only protein specific, but can also be pH specific and is therefore methionine is not known as a common stabilizer. The literature also discloses that the use of methionine as a stabilizer is very dependent upon the protein and the conditions of the formulation.

These arguments have been considered, and are found persuasive in part. The '225 patent teaches all of the limitations of the claimed invention, except for the use of methionine and polyethylene glycol. The '708 patent teaches the use of methionine as a stabilizer for three different proteins, (G-CSF, interferon-alpha and IL-4) at different pH conditions, and showed that the addition of methionine extended storage life for all three proteins, (see examples 1-4). With respect to the use of polyethylene glycol, Cleland et al reference teaches human growth hormone that is formulated with polyethylene glycol and demonstrates that both stability and yield are improved. One skilled in the art would be motivated to modify the growth hormone formulations of the '225 reference by using methionine as a stabilizer, because the '708 reference teaches that the advantages of using methionine is that it extends storage life. One would also be motivated to modify the growth hormone formulations of the '225 reference by adding polyethylene glycol to said formulations, because Cleland et al reference teaches that polyethylene glycol

increases stability and yield. Accordingly, the combined teachings of '225, '708 and Cleland et al render the claimed invention obvious.

***Conclusion:***

4. No claim is allowed.

***Advisory Information:***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to FOZIA M. HAMUD whose telephone number is (571)272-0884. The examiner can normally be reached on Monday-Friday: 8:00 am to 4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary B. Nickol can be reached on (571) 272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Fozia Hamud  
Patent Examiner  
Art Unit 1647  
22 July 2010

/Bridget E Bunner/  
Primary Examiner, Art Unit 1647